CYTOX-LIMITED
Cytox , a precision medicine company which today is commercializing polygenic risk scoring (PRS) approaches for assessing genetic risk for developing Alzheimer’s (AD) and other neurological diseases, has announced that in collaboration with Cardiff University it will be making a poster and short oral presentation at the multidisciplinary 14th International Conference on Alzheimer’s and Parkinson’s Diseases and related neurological disorders (AD/PD™ 2019 ), March 26-31 in Lisbon, Portugal. The presentation will share results on the high accuracy of Cytox’s pioneering SNPfitRTM , an analytical software platform that contains multiple PRS algorithms, in predicting clinical Alzheimer’s disease in both carriers and non-carriers of ApoE4 risk allele, with validation and optimization in independent, well-characterized cohorts, including the Alzheimer's Disease Neuroimaging Initiative (ADNI). In addition, the prediction accuracy in carriers was significantly increased compared with the accuracy achieved using ApoE (E4/E2), age and gender.
Poster 249, ‘The Utility of Polygenic Risk Scores to Identify Individuals for Clinical Trials in Alzheimer’s Disease’, will be displayed all day on March 27th , as part of the ‘Imaging, Biomarkers, Diagnostics: Other’ session in the Exhibition Hall at the Lisbon Congress Centre and an oral presentation will be given by Eftychia Bellou, Cardiff University, Cardiff, United Kingdom, in the Short Oral Session 02 – Presentations of Selected Posters on March 28th , 09:15 - 11:15, Auditorium V.
Richard Pither, CEO of Cytox, commented “The importance of Cytox’s PRS approach is gaining increasing attention for estimating individual genetic risk profile and disease risk prediction in Alzheimer’s – essential in the selection of individuals for clinical trials and cohort studies. Recent results from an international collaborative study have validated this, including how we identify Alzheimer’s disease risk in ApoE3 homozygote individuals. The results we are presenting at AD/PD further show that SNPfitR provides a valuable platform for determining genetic risk in dementia in both carriers and non-carriers of ApoE4, with the advantage of requiring only blood or saliva-extracted DNA, thus reducing reliance on expensive PET imaging procedures.”
View source version on businesswire.com: https://www.businesswire.com/news/home/20190312005741/en/
Contact:
Cytox Limited Richard Pither, CEO +44(0)1865338018 richard.pither@cytoxgroup.com www.cytoxgroup.com
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Mary Kay Ash Foundation® Gifts $500,000 Grant to Advance Cancer Research and Early Detection at Baylor Scott & White Health13.11.2025 14:01:00 CET | Press release
Funding includes support for groundbreaking clinical trial and multi-year gift to Texas Cancer Interception Institute; Foundation honored with Circle of Care Award for two decades of partnership The Mary Kay Ash Foundation®, a champion of women’s health innovation for nearly three decades, announced a $500,000 grant to Baylor Scott & White Dallas Foundation to accelerate a pioneering triple-negative breast cancer clinical trial and advance early detection initiatives that shift care from reactive to proactive at the newly established Texas Cancer Interception Institute. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251113339900/en/ In recognition of its steadfast, decades-long commitment to women’s health, the Mary Kay Ash Foundation was honored with the prestigious Circle of Care Award at the 2025 Celebrating Women Luncheon, hosted by the Baylor Scott & White Dallas Foundation. The award celebrates those who have made a pr
Owkin Announces Availability of K Pro in the AWS Marketplace SaaS Category13.11.2025 14:00:00 CET | Press release
Owkin, a leading provider of agentic AI solutions for biopharma, today announced the availability of K Pro in the SaaS category of AWS Marketplace. Customers can now use AWS Marketplace to easily discover, buy, and deploy AI agents solutions, including Owkin’s agentic AI co-pilot for biopharma using their AWS accounts, accelerating agent and agentic workflow development. K Pro helps organizations make smarter decisions across their discovery and development pipeline by delivering decision-grade, data-driven biological insights, enabling customers to increase clinical success rates and change program trajectories. "By offering K Pro in AWS Marketplace we're providing customers with a streamlined way to access our agentic AI co-pilot, helping them buy and deploy agent solutions faster and more efficiently." said Adi Ravia, Head of Product at Owkin. "Our customers in biotech, pharmaceuticals and research are already using these capabilities to access and analyse deep multimodal patient da
ChargePoint Releases Next-Generation Software Platform to Manage Any EV Charging Operation, from Fleets to Employee Parking13.11.2025 14:00:00 CET | Press release
ChargePoint (NYSE: CHPT), a global leader in electric vehicle (EV) charging solutions, has released a new generation of the ChargePoint Platform, a flexible software solution designed to redefine EV charging. Re-engineered from the ground up, the ChargePoint Platform empowers operators to optimize any charging infrastructure, from a single site to a global network, while ensuring seamless integration with evolving energy systems. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251112330917/en/ ChargePoint has released a new generation of the ChargePoint Platform, a flexible software solution designed to redefine EV charging. “The new ChargePoint Platform is more than just modernized software, it is a catalyst for an electrified future,” said Rick Wilmer, Chief Executive Officer at ChargePoint. “ChargePoint has manifested our deep expertise in EV charging to deliver the industry’s most advanced software platform, which is comp
360Learning Integrates with Workday Learning to Transform Enterprise Learning Experiences13.11.2025 14:00:00 CET | Press release
360Learning, the AI-powered collaborative learning platform that enables organisations to upskill from within, is announcing the integration of its Learning Experience Platform (LXP) into Workday’s Learning platform. Through this integration, 360Learning will enable enterprise organizations to launch AI-powered collaborative learning Academies and help deliver timely upskilling to all learners. Workday Learning customers can now leverage internal subject-matter experts to create impactful training in minutes using 360Learning's AI-powered authoring tools – a process that previously took months. Benjamin Marchal, CEO at 360Learning, said: "This partnership helps support career and company growth, enabling learning teams to build programs that meet today's speed of business. By empowering internal experts with AI-powered authoring tools and collaborative learning capabilities, organizations can preserve and distribute proprietary knowledge to increase the impact of their L&D investment."
REPLY: The Board of Directors Approves the Quarterly Financial Report as of 30 September 202513.11.2025 13:23:00 CET | Press release
All economic indicators have substantially improved:Consolidated turnover of €1,819.8 million (1,669.6 as at 30 September 2024)EBITDA of €335.5 million (275.5 as at 30 September 2024)EBIT of €281.0 million (224.2 as at 30 September 2024)Pre-tax profit of €268.1 million (216.0 as at 30 September 2024)Positive Net Financial Position of €423.1 million. Today, the Board of Directors of Reply [EXM, STAR: REY] approved the results as at 30 September 2025. The Group's consolidated turnover in the first nine months of the year reached €1,819.8 million, an increase of 9.0% compared to €1,669.6 million recorded on 30 September 2024. The indicators for the period are positive. Consolidated EBITDA was €335.5 million, equal to 18.4% of the consolidated revenues. As of September 2024 EBITDA was €275.5 million. EBIT, from January to September, reached €281.0 million, equal to 15.4% of the consolidated revenues. The corresponding 2024 figure was €224.2 million. Pre-tax profit, from January to Septembe
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom